INTRODUCTION
The mammalian conceptus is antigenically different from the mother, and yet immunological rejection of the fetus does not normally occur. Lack of immunological rejection has generally been attributed to depressed cell-mediated phenomena of the mother during pregnancy (1) (2) (3) (4) (5) . Evidence has been presented demonstrating factors present in pregnancy plasma capable of limiting as well as inhibiting those in vitro responses representative of cell-mediated immunity (6) (7) (8) (9) . Hormones such as gonadotropin (10, 11) , corticosteroids (12) , progesterone (13) , plasma proteins (14, 15) , and serum blocking antibodies (16, 17) are synthesized by the placenta and have been demonstrated to suppress in vitro responses associated with cell-mediated immunity.
The steroid hormone, cortisol, elevated to very high levels with continuation of pregnancy, is a potent suppressor of cell-mediated phenomena. The repressive action of cortisol on the lymphocyte is considered to be dependent upon the presence of a specific cortisol receptor protein of the lymphocyte's cytoplasm (18) (19) (20) . We have recently demonstrated that the maj or cortisolbinding protein of the human lymphocyte is chemicophysically similar and immunologically identical to transcortin, the cortisol-binding globulin of human plasma (21) . Furthermore, this protein is actively transported into the lymphocyte' and is postulated to interfere with the protein-synthetic apparatus of the cell (22) . Transcortin is markedly and continuously increased during pregnancy (23, 24) . This increase is due to increased synthesis induced by elevations of plasma estrogens (25, 26) and occurs exclusively in the liver (27, 28) . It is possible, therefore, that increased levels of transcortin could result in the suppression of cell-mediated immunity. If transcortin has a central role in dampening the cell-mediated immune activity of those lymphocytes responding to the presence of the antigenic fetus, it seemed logical to us to expect that perhaps the action of transcortin might be more immediately potent if its site of synthesis and release were the placenta. Placental synthesis of transcortin would also result in delimiting the activity of T lymphocytes in the vicinity of the placenta, with perhaps lesser systemic effects on the mother, for she must continue to have operable "immunological surveillance." This study investigated the question of whether transcortin is present in the fetal placental unit and whether the purified placental 
METHODS
The purification of human plasma transcortin, its characterization, and the preparation of a transcortin-specific antibody have been previously described (21) .
In situ localization of intracellular transcortin. Smears of human lymphocytes or frozen sections of human placenta were air-dried, immersed in ice-cold acetone, and coated with fluorescein-labeled transcortin-specific antibody (21) .
After suitable washing with phosphate-buffered saline, the slides were mounted with a mixture of 50% glycerol-phosphate saline solution and studied with a Leitz fluorescence microscope (E. Leitz, Inc., Rockleigh, N. J. (21) .
Disc-acrylamide electrophoresis of purified placental transcortin. 0.1 mg of the purified hydroxylapatite (HAP) II fraction was layered on top of disc acrylamide electrophoretic columns (0.5 X 7.0 cm) containing a 10% acrylamide separation gel. Electrophoresis was conducted as described by Ornstein (32) and Davis (33) .
The effect of placental transcortin on PHA-induced blast transformation by human lymphocytes. Human lymphocytes, purified by methods previously described (22, 34) were suspended in autologous plasma at a concentration of 25 X 106 cells/ml of plasma. 0.1 ml of these suspensions was added to 1 ml of TC-199 medium containing penicillin (100 U/ml) and streptomycin (10 mg/ml) and 0.25 ml of PHA-P (Difco Laboratories, Detroit, Mich.). To half of these cultures, approximately 0.1 mg of purified placental transcortin was added. All cultures were incubated for up to 3 days at 370C in a 5% C02 atmosphere mixture. At the end of designated intervals each of the cultures received 1 ,uCi of [3H]thymidine (sp act 33 Ci/mM) and the cultures were incubated for 2 h at 37°C. Incorporation of [3H]thymidine by cultured cells was determined by methods previously described (22) . In addition, the cultured cells were smeared, and the percentage of lymphocytes transformed was determined by microscopic evaluation by two independent investigators. In all cases, agreement of such analysis did not deviate by more than ±3% of the mean between the two sets of analysis.
RESULTS

Quantitation of intracellular lymphocyte transcortin
Previously we demonstrated that the human lymphocyte contains within its cytoplasm a protein species with many of the physicochemical properties of transcortin (21) . In situ identification of this transcortinlike protein was afforded by the application of a fluorescein-labeled transcortin antibody to smears of peripheral blood lymphocytes. It was noted that almost all of the fluorescence was limited to the cytoplasmic rim of the lymphocyte. Controls demonstrated that such fluorescence was not due to membrane-bound transcortin (21) .
We have attempted to measure the level of intracellular transcortin of peripheral blood lymphocytes during pregnancy. Our reasons for attempting this analysis stem from studies demonstrating that trans- cortin levels are markedly elevated during pregnancy (23, 24) . Since transcortin is found within the lymphocyte and since lymphocytes do not appear to synthesize transcortin, the possibility that increased plasma levels of transcortin would result in increases of intracellular lymphocyte transcortin seemed worthy of investigation. The use of serial dilutions of the fluoresceinlabeled transcortin antibody to quantitate the relative level of lymphocyte intracellular transcortin illustrates that this level increases with continuation of pregnancy and reaches a maximum during the third trimester (Table I) . It should be noted from the data presented that the range of D5o is rather narrow within the normal (nonpregnant) group of women (1 :40-1:80). However, during the first trimester the D5o increases as well as its range. The range of D50 continues to increase during the second trimester. It is during the third trimester, however, that the levels of intracellular transcortin are truly significantly different from those of the normal. Within this group, 12 of the 14 individuals had a D50 of 1:640. Immediately before parturition, the intracellular transcortin level drops to within the normal range.
In situ localization of transcortin within placental cells Biosynthetically plasma transcortin has been considered to originate exclusively in the liver (27, 28) . Furthermore, administration of estrogens or their synthetic analogues results in a maximal twofold increase in plasma transcortin levels (35) , suggesting that the maximum synthesis in the liver might be limited. However, transcortin levels in pregnant women reach much higher levels (23, 24) , suggesting in turn that perhaps another organ or organs might be synthesizing this protein as well. To determine whether the placenta might synthesize and/or contain transcortin, we applied the fluorescein-labeled transcortin antibody to frozen sections of a full-term human placenta. Fig. 1 Determination of cortisol binding by placental cytosol
The above studies on the human placenta suggest that placental tissue contains a protein(s) recognized by the transcortin-specific antibody. Additional evidence suggesting that the placenta indeed contains transcortin is provided by the determination of cortisol binding by the G-25 Sephadex filtration of DeMoor et al. (30) . From the data presented in Fig. 2 , it is clear that the placental cytosol contains species capable of rigorously binding cortisol (front-running radioactivity peak).
Purification of placenta transcortin
The above findings suggest that the placenta contains species of protein that bind cortisol and are recognized by a transcortin-specific antibody. To determine whether the above species are indeed transcortin, their purification was attempted via the methods used for the purification of transcortin. Passage of ['H]cortisol-placental cytosol through a water-equilibrated DEAE column and subsequent washing of the column with water, followed by elution with buffer, yielded an ['H]cortisol elution profile depicted in Fig. 3 . Under the elution conditions listed in the legend of Fig. 3 , a single radioactive peak coinciding with an optical density peak at This pooled post-DEAE fraction was split into two portions, one rapidly frozen and stored at -700C, the other portion passed through a HAP column. Elution of the applied material yielded two radioactivity peaks labeled HAP I and HAP II in Fig. 4 . Only the HAP II fraction exhibited strong cortisol-binding activity, demonstrable via G-25 Sephadex methods, as previously described. This HAP II fraction was passed through two additional HAP columns, the last of which exhibited a single ['H]cortisol peak coinciding with a single optical density peak at 280 nm. Lyophilization with subsequent dialysis against saline was carried out. ation of sedimentation coefficients for the placental intracellular transcortin during various stages of its purification was accomplished. Fig. 6 illustrates that plasma transcortin contains a single [8H]cortisol peak corresponding to a sedimentation coefficient of 3.6-3.8. Similar treatment of the placental cytosol yields two radioactive peaks of 3 and 4.5S (Fig. 7) . The 3S peak is very broad and hence any minor species sediment- 21 ).
ing as a plasma transcortin component would be masked. However, the sedimentation profile obtained after the first passage through HAP columns yields a profile similar to that of the cytosol (Fig. 8) . It should be noted that no sedimentation activity peak corresponding to that of plasma transcortin was evident at any point during purification. Disc acrylamide electrophoretic analysis. In accordance with differences in sedimentation behavior in sucrose gradients between the HAP II fraction and plasma transcortin, Fig. 9 illustrates that HAP II fraction and transcortin are electrophoretically dissimilar. It is clear that HAP II fraction migrates in this system with more mobility than purified transcortin.
Effect of purified placental transcortin on the PHA response
To determine whether the placental fraction (exhibiting many of the characteristics of transcortin) inhibits in vitro responses associated with cell-mediated immunity, human lymphocytes, obtained from normal women, were incubated with and without placental fraction HAP II or with purified human transcortin to which cortisol was tightly bound. The results, presented 6~3 .6-3.8S In addition, the presence of transcortin inhibits such incorporation by only 35%.
DISCUSSION
The results presented in this study demonstrate that the cytoplasm of syncytiotrophoblastic cells of the human placenta contains a protein with immunologic and physicochemical characteristics similar to that of plasma transcortin. However, this molecule differs from trans- In our previous studies, we have suggested that plasma transcortin may be transported into the human lymphocyte (22, 34) and that the transcortin present within the cytoplasm of the human lymphocyte is smaller than plasma transcortin and very similar in its physicochemical characteristics to partially purified placental transcortin (21) . Studies submitted elsewhere provide strong support for this contention by showing that cultured human lymphocytes of the cell line R-PMI-1788 transport this protein from the medium to their cytoplasm. 1 We have suggested that soon after the transport of transcortin-cortisol complexes into the lymphocyte, an enzyme acts on this complex, thereby removing cortisol (this cortisol is rapidly and actively extruded [34] ) and thereby yielding a small polypeptide (21) . After this enzymatic action, the resulting transcortin has a smaller cortisol-binding capacity and a smaller sedimentation coefficient. We have postulated that this modified transcortin inhibits the synthesis of lymphocyte protein (21, 22) . We feel that, unlike the lymphocyte, biosynthesis of the placental transcortin possibly occurs within placental cells. To date, however, only the liver has been identified as the exclusive site of transcortin biosynthesis (27, 28) .
It is presumed that placental transcortin, like transcortin in the liver, is induced by maternal secretions of estrogen. Support for this hypothesis may be found in those studies that demonstrate that the biosynthesis of transcortin is induced by estrogen and that increases in plasma estrogen during pregnancy are paralleled by increases in maternal plasma transcortin (25, 26) . We feel that during the first trimester, the increased level of transcortin in maternal plasma is the result of its induced biosynthesis by the liver in response to estrogenic increases. However, the absolute limit of transcortin levels resulting from estrogenic induction is probably equal to that observed in men receiving diethylstilbestrol, about 6-12 mg of transcortin/100 ml of plasma (35) . Since the total level of maternal plasma transcortin is much higher during the second, and still higher during the third trimester (23) , this total level may possibly involve transcortin molecules of placental origin.
Although we have not measured plasma transcortin levels before parturition in this study, we have measured the level of lymphocyte intracellular transcortin during pregnancy. Our results suggest that during gestation peripheral lymphocytes contain increasing levels of cytoplasmic transcortin. These increases parallel those observed in plasma and may result from an increase in transcortin transport into the lymphocyte. However, unlike the transport of plasma transcortincortisol complexes, only the modified transcortin of placental origin enters the lymphocyte. It is this modified protein that can limit the cell-mediated immune response to a much greater degree than the unadulterated transcortin-cortisol complex.
The presence of large amounts of transcortin within placental cells at time of parturition might at first seem to contradict the above hypothesis. It is suggested, however, that the transcortin observed in full-term placental cells might simply reflect an accumulation due to diminished secretion of this protein. This diminished secretion might be the result of an increase in the rate that estrogens are metabolized by the placenta. Support for this contention is provided by those studies that show that in liver, estrogen controls the release of transcortin to the circulatory system (27) . Accordingly, our hypothesis would then predict that maternal cellmediated immunity would now be fully operational. At this point, the placenta and fetus are rejected much as any foreign antigenic tissue would be rejected in the mammal. Evidence of such cell-mediated responses occurring at this time are routinely found in uterine tissues (36) .
The above general theory is far from proved. Our studies only support the general theory at critical points. It remains for future studies, some in progress, to elucidate further.
